1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Tolfine

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance
Tolfenamic acid 40 mg

Excipients
Benzyl alcohol 10.4 mg

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection.

4. CLINICAL PARTICULARS

4.1 Target species

Cattle and Pigs.

4.2 Indications for use, specifying the target species

Tolfine is indicated:
- In cattle, as an adjunct in the treatment of pneumonia by improving general conditions and nasal discharge and as an adjunct in the treatment of acute mastitis.
- In pigs, as an adjunct in the treatment of Metritis Mastitis Agalactia syndrome.

4.3 Contraindications

Do not use in case of hypersensitivity to the active substance.

4.4 Special warnings for each target species

Do not exceed 20 ml per injection site.

4.5 Special precautions for use

Special precautions for use in animals

Do not exceed the stated dosage and duration of treatment.
Use aseptic precautions when administering the product.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

None known.

4.6 Adverse reactions (frequency and seriousness)

There are occasional reports of collapse following rapid intravenous injection in cattle.

When administering intravenously, the product should be injected slowly. At the first signs of intolerance, the injection should be interrupted.
Transient inflammation and swelling may commonly occur at the injection site lasting up to 38 days.
Hypersensitivity reactions, including anaphylaxis (sometimes fatal), have been reported very rarely.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

The product may be used during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of interaction

Do not administer other NSAIDs concurrently or within 24 hours of each other. Tolfenamic acid is highly bound to plasma proteins and may compete with other highly bound drugs.

4.9 Amounts to be administered and administration route

For inflammation associated with respiratory disease in cattle, the recommended dosage is 2 mg/kg (1 ml/20 kg bodyweight) by intramuscular injection into the neck area. Treatment may be repeated once after 48 hours.

For use in mastitis, the recommended dosage is 4 mg/kg bodyweight (1 ml per 10 kg bodyweight) as a single IV injection.

In pigs, the recommended dosage is 2 mg/kg (1 ml/20 kg bodyweight) as a single intramuscular injection.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

None known.

4.11 Withdrawal period(s)

Cattle
I.M. injection
Meat and offal: 12 days
Milk: 0 hours.

I.V. injection
Meat and offal: 4 days
Milk: 24 hours.

Pigs
Meat and offal: 16 days.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Musculo-skeletal system, anti-inflammatory and antirheumatic products, non-steroids, fenamates, tolfenamic acid.

ATC vet code: QM01AG02

5.1 Pharmacodynamic properties

Tolfenamic acid (N-(2-methyl-3-chlorophenyl) anthranilic acid) is a non-steroidal anti-inflammatory drug (NSAID) belonging to the fenamate group. Tolfenamic acid exerts anti-inflammatory, analgesic and antipyretic activities.
The anti-inflammatory activity of tolfenamic acid is mainly due to an inhibition of cyclo-oxygenase and thus to a reduction of the synthesis of prostaglandins and thromboxanes, which are important inflammatory mediators.

5.2 Pharmacokinetic particulars

In cattle and pigs, tolfenamic acid injected by IM route at a dose of 2mg/kg is rapidly absorbed from the injection site with mean maximum plasma concentrations of about 1.4 µg/ml in cattle and 2.3 µg/ml in pigs obtained at about 1 hour.

The volume of distribution is about 1.3 1/kg in cattle and pigs.

It is extensively bound to plasma albumin (>97%).

Tolfenamic acid is distributed in all the organs with a high concentration in the plasma, digestive tract, liver, lungs and kidneys. However, the concentration in the brain is low. Tolfenamic acid and its metabolites do not cross the placenta to any great extent.

Tolfenamic acid distribution involves extracellular fluids where concentrations similar to plasma are achieved both in healthy and inflamed peripheral tissues. It also appears in milk in the active form, mainly associated with the curds.
Tolfenamic acid undergoes extensive enterohepatic recirculation and, as a result prolonged concentrations are found in plasma.

The elimination half life varies from 3-5 hours in pigs to 8-15 hours in cattle.

In cattle and pigs, tolfenamic acid is eliminated mainly unchanged in faeces (~30%) and urine (~70%).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Ethyldiglycol
Benzyl Alcohol
Ethanolamine
Water for injections

6.2 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 28 days

6.4. Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

6.5 Nature and composition of immediate packaging

The product Tolfine is packaged in amber type I glass vials of 50 ml, 100 ml and 250 ml.
The vials are closed with a chlorobutyl rubber stopper with aluminium flip cap.
Each vial is packaged in a cardboard box.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Vetoquinol Ireland Limited

8. MARKETING AUTHORISATION NUMBER(S)

VPA10983/031/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

04/02/2000

10 DATE OF REVISION OF THE TEXT

13/08/2024